Next Article in Journal
Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics
Next Article in Special Issue
Nemo-Like Kinase in Development and Diseases: Insights from Mouse Studies
Previous Article in Journal
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine
Previous Article in Special Issue
Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib
 
 
Review
Peer-Review Record

Targeting Casein Kinase 1 (CK1) in Hematological Cancers

Int. J. Mol. Sci. 2020, 21(23), 9026; https://doi.org/10.3390/ijms21239026
by Pavlína Janovská 1, Emmanuel Normant 2, Hari Miskin 2 and Vítězslav Bryja 1,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(23), 9026; https://doi.org/10.3390/ijms21239026
Submission received: 24 October 2020 / Revised: 20 November 2020 / Accepted: 21 November 2020 / Published: 27 November 2020
(This article belongs to the Special Issue Protein Kinases: Function, Substrates, and Implication in Diseases)

Round 1

Reviewer 1 Report

In the present review Janovska et al provide an updated overview of the role of the casein kinase (CK1) family of enzymes in hematological malignancies, with special focus on the development of CK1 inhibitors with therapeutic potential.

Overall, I find the review well written and very informative, as it includes a lot of the recent work on CK1 inhibitor research. I do not have any major concerns or corrections.

As a minor comment, I would suggest a rephrasing of the sentence included in lines 122-124 (page 4), since the "not only" included in parenthesis is confusing for the reader. Hematological malignancies are indeed cancers, so the sentence does not really make sense as it stands. I assume the authors want to stress the potential importance of CK1 inhibitors in non-hematological malignancies (as stated in the title of the section).

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Diligent and comprehensive review article targeting all relevant aspects of the role of CK1 enzymes for different lymphatic and myeloid malignancies. Preclinical and clinical studies evaluating different CK1 inhibitors are described. No critizisms from my side. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop